Patents by Inventor Magnus Doverskog

Magnus Doverskog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GOLEXANOLONE FOR USE IN THE TREATMENT OF FATIGUE OR COGNITIVE IMPAIRMENT IN LIVER DISEASE PATIENTS
    Publication number: 20240216394
    Abstract: The present invention is directed to the compound golexanolone or a pharmaceutically acceptable salt thereof for use in the treatment of fatigue or cognitive impairment, or a combination thereof, in a non-cirrhotic patient with a chronic liver disease, wherein the patient has a serum level of allopregnanolone which is 0.03 ng/ml or higher.
    Type: Application
    Filed: April 19, 2022
    Publication date: July 4, 2024
    Inventors: Magnus Doverskog, Maja Johansson, Lars Öhman, David Jones
  • NEW MEDICAL TREATMENT
    Publication number: 20230134958
    Abstract: The present invention is directed to a method for the treatment of cognitive impairment in a cirrhotic patient with hepatic encephalopathy (HE), said patient having a CRT index (continous reaction time index) below 1.9 at baseline (prior to treatment), whereby the compound golexanolone (3?-ethynyl-3?-hydroxyandrostan-17-one oxime) of formula (I) or a pharmaceutically acceptable salt thereof, is administered to said patient.
    Type: Application
    Filed: October 28, 2022
    Publication date: May 4, 2023
    Inventors: Magnus Doverskog, Mette Lauridsen, Bruce Frederick Scharschmidt
  • Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
    Patent number: 11123351
    Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: September 21, 2021
    Assignee: Umecrine Cognition AB
    Inventors: Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper
  • PHARMACEUTICAL FORMULATION OF 3-ALPHA-ETHYNYL-3-BETA-HYDROXYANDROSTAN-17-ONE OXIME
    Publication number: 20200297737
    Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.
    Type: Application
    Filed: February 21, 2020
    Publication date: September 24, 2020
    Inventors: Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper
  • Pharmaceutical formulation of 3?-ethynyl-3?-hydroxyandrostan-17-one oxime
    Patent number: 10603326
    Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: March 31, 2020
    Assignee: Umecrine Cognition AB
    Inventors: Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper
  • PHARMACEUTICAL FORMULATION OF 3ALPHA -ETHYNYL-3BETA-HYDROXYANDROSTAN-17-ONE OXIME
    Publication number: 20190358244
    Abstract: The present invention is directed to a novel pharmaceutical formulation comprising 3?-ethynyl-3?-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.
    Type: Application
    Filed: June 24, 2019
    Publication date: November 28, 2019
    Inventors: Paul Alhadeff, Magnus Doverskog, Maja Johansson, Thomas Meijer, Nicolaas Schipper
  • Steroid compound for use in the treatment of hepatic encephalopathy
    Patent number: 10342804
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: July 9, 2019
    Assignee: Umecrine Cognition AB
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
  • Methods for treating hypersomnolence
    Patent number: 10278977
    Abstract: There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3?-ethynyl-3?-hydroxy-5?-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: May 7, 2019
    Assignee: Umecrine Cognition AB
    Inventors: Torbjörn Bäckström, Magnus Doverskog, Maja Johansson, Pontus Wasling
  • STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY
    Publication number: 20180015103
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
  • METHODS AND MEDICAL USES
    Publication number: 20170348323
    Abstract: There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3?-ethynyl-3?-hydroxy-5?-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 7, 2017
    Inventors: Torbjörn Bäckström, Magnus Doverskog, Maja Johansson, Pontus Wasling
  • Steroid compound for use in the treatment of hepatic encephalopathy
    Patent number: 9801894
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: October 31, 2017
    Assignee: Umecrine Cognition AB
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
  • STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY
    Publication number: 20170056416
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Application
    Filed: November 15, 2016
    Publication date: March 2, 2017
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
  • STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY
    Publication number: 20160339040
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Application
    Filed: January 14, 2015
    Publication date: November 24, 2016
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjöm Bäckström